These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

95 related items for PubMed ID: 8041200

  • 21. Study of intermittent intravenous deferrioxamine high-dose therapy in heavily iron-loaded children with beta-thalassemia major poorly compliant to subcutaneous injections.
    Wali YA, Taqi A, Deghaidi A.
    Pediatr Hematol Oncol; 2004; 21(5):453-60. PubMed ID: 15205089
    [Abstract] [Full Text] [Related]

  • 22. [Arrhythmia in thalassemia major: evaluation of iron chelating therapy by dynamic ECG].
    Cavallaro L, Meo A, Busà G, Coglitore A, Sergi G, Satullo G, Donato A, Calabrò MP, Miceli M.
    Minerva Cardioangiol; 1993; 41(7-8):297-301. PubMed ID: 8233011
    [Abstract] [Full Text] [Related]

  • 23. [Evaluation of iron overload in thalassemia].
    Piga A, Davico S, Magliano M, Luzzatto L, Sandri A, Gabutti V.
    Pediatr Med Chir; 1986; 8(1):9-13. PubMed ID: 3725619
    [Abstract] [Full Text] [Related]

  • 24. Endocrine complications in patients with Thalassaemia Major.
    Toumba M, Sergis A, Kanaris C, Skordis N.
    Pediatr Endocrinol Rev; 2007 Dec; 5(2):642-8. PubMed ID: 18084158
    [Abstract] [Full Text] [Related]

  • 25. [Long-term effects of combined therapy in patients with beta-thalassemia major].
    Bagnulo S, Giannini AM, Moscatelli F, Stragapede L, Acquafredda A, Dammacco A.
    Pediatr Med Chir; 1998 Dec; 20(1):33-7. PubMed ID: 9658419
    [Abstract] [Full Text] [Related]

  • 26. [Therapeuetic management of patients with thalassemia major].
    Thuret I.
    Bull Soc Pathol Exot; 2001 May; 94(2):95-7. PubMed ID: 11475036
    [Abstract] [Full Text] [Related]

  • 27. Prevalence of endocrine complications and short stature in patients with thalassaemia major: a multicenter study by the Thalassaemia International Federation (TIF).
    De Sanctis V, Eleftheriou A, Malaventura C, Thalassaemia International Federation Study Group on Growth and Endocrine Complications in Thalassaemia.
    Pediatr Endocrinol Rev; 2004 Dec; 2 Suppl 2():249-55. PubMed ID: 16462705
    [Abstract] [Full Text] [Related]

  • 28. Beta-thalassemia and pulmonary function.
    Piatti G, Allegra L, Ambrosetti U, Cappellini MD, Turati F, Fiorelli G.
    Haematologica; 1999 Sep; 84(9):804-8. PubMed ID: 10477453
    [Abstract] [Full Text] [Related]

  • 29. Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major.
    Wolfe L, Olivieri N, Sallan D, Colan S, Rose V, Propper R, Freedman MH, Nathan DG.
    N Engl J Med; 1985 Jun 20; 312(25):1600-3. PubMed ID: 4000198
    [Abstract] [Full Text] [Related]

  • 30. Impact of long-term iron chelation therapy on growth and endocrine functions in thalassaemia.
    De Sanctis V, Roos M, Gasser T, Fortini M, Raiola G, Galati MC, Italian Working Group on Endocrine Complications in Non-Endocrine Diseases.
    J Pediatr Endocrinol Metab; 2006 Apr 20; 19(4):471-80. PubMed ID: 16759032
    [Abstract] [Full Text] [Related]

  • 31. Pulmonary function abnormalities in thalassemia major and the role of iron overload.
    Factor JM, Pottipati SR, Rappoport I, Rosner IK, Lesser ML, Giardina PJ.
    Am J Respir Crit Care Med; 1994 Jun 20; 149(6):1570-4. PubMed ID: 8004315
    [Abstract] [Full Text] [Related]

  • 32. Compliance of deferoxamine injection in beta-thalassaemia major patients in Iran.
    Rashid M, Karimi M.
    Transfus Med; 2012 Apr 20; 22(2):104-7. PubMed ID: 22212011
    [Abstract] [Full Text] [Related]

  • 33. [Beta-pancreatic function in subjects with thalassemia. A 4-year follow-up].
    Zanini R, Briante G, Cantone P, Sticca M, Grasso U.
    Pediatr Med Chir; 1985 Apr 20; 7(5):749-53. PubMed ID: 3915549
    [Abstract] [Full Text] [Related]

  • 34. Glucose tolerance and chelation therapy in patients with thalassaemia major.
    Capra L, Atti G, De Sanctis V, Candini G.
    Haematologica; 1983 Apr 20; 68(1):63-8. PubMed ID: 6404709
    [No Abstract] [Full Text] [Related]

  • 35. [Ocular findings in Desferal therapy].
    Dennerlein JA, Lang GE, Stahnke K, Kleihauer E, Lang GK.
    Ophthalmologe; 1995 Feb 20; 92(1):38-42. PubMed ID: 7719074
    [Abstract] [Full Text] [Related]

  • 36. Prolonged survival in patients with beta-thalassemia major treated with deferoxamine.
    Ehlers KH, Giardina PJ, Lesser ML, Engle MA, Hilgartner MW.
    J Pediatr; 1991 Apr 20; 118(4 Pt 1):540-5. PubMed ID: 2007928
    [Abstract] [Full Text] [Related]

  • 37. The effects of subcutaneous deferoxamine administration on renal function in thalassemia major.
    Koren G, Kochavi-Atiya Y, Bentur Y, Olivieri NF.
    Int J Hematol; 1991 Oct 20; 54(5):371-5. PubMed ID: 1756248
    [Abstract] [Full Text] [Related]

  • 38. Effect of different treatment regimes on linear growth and final height in beta-thalassaemia major.
    De Sanctis V, Katz M, Vullo C, Bagni B, Ughi M, Wonke B.
    Clin Endocrinol (Oxf); 1994 Jun 20; 40(6):791-8. PubMed ID: 8033371
    [Abstract] [Full Text] [Related]

  • 39. Growth impairment in beta-thalassemia major: the role of trace element deficiency and other potential factors.
    Eshghi P, Alavi S, Ghavami S, Rashidi A.
    J Pediatr Hematol Oncol; 2007 Jan 20; 29(1):5-8. PubMed ID: 17230059
    [Abstract] [Full Text] [Related]

  • 40. [Growth velocity in thalassemic children receiving different protocols of chelating therapy].
    Elena MG, Fedele A, Gianino P, Giordanino S, Murru P, Tosi C, Vannelli S.
    Minerva Pediatr; 1992 Jan 20; 44(1-2):41-2. PubMed ID: 1552875
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.